![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MSMO1 |
Gene summary for MSMO1 |
![]() |
Gene information | Species | Human | Gene symbol | MSMO1 | Gene ID | 6307 |
Gene name | methylsterol monooxygenase 1 | |
Gene Alias | DESP4 | |
Cytomap | 4q32.3 | |
Gene Type | protein-coding | GO ID | GO:0006066 | UniProtAcc | Q15800 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6307 | MSMO1 | LZE4T | Human | Esophagus | ESCC | 2.22e-16 | 9.20e-01 | 0.0811 |
6307 | MSMO1 | LZE5T | Human | Esophagus | ESCC | 5.55e-04 | 7.22e-01 | 0.0514 |
6307 | MSMO1 | LZE7T | Human | Esophagus | ESCC | 1.30e-07 | 6.58e-01 | 0.0667 |
6307 | MSMO1 | LZE24T | Human | Esophagus | ESCC | 1.10e-03 | 1.90e-01 | 0.0596 |
6307 | MSMO1 | LZE6T | Human | Esophagus | ESCC | 2.60e-08 | 3.77e-01 | 0.0845 |
6307 | MSMO1 | P2T-E | Human | Esophagus | ESCC | 1.20e-19 | 3.45e-01 | 0.1177 |
6307 | MSMO1 | P4T-E | Human | Esophagus | ESCC | 6.81e-45 | 1.56e+00 | 0.1323 |
6307 | MSMO1 | P5T-E | Human | Esophagus | ESCC | 2.18e-34 | 9.10e-01 | 0.1327 |
6307 | MSMO1 | P8T-E | Human | Esophagus | ESCC | 2.50e-11 | 2.01e-01 | 0.0889 |
6307 | MSMO1 | P9T-E | Human | Esophagus | ESCC | 6.07e-09 | 3.53e-01 | 0.1131 |
6307 | MSMO1 | P10T-E | Human | Esophagus | ESCC | 2.47e-60 | 1.81e+00 | 0.116 |
6307 | MSMO1 | P11T-E | Human | Esophagus | ESCC | 9.29e-15 | 7.13e-01 | 0.1426 |
6307 | MSMO1 | P12T-E | Human | Esophagus | ESCC | 2.31e-16 | 4.16e-01 | 0.1122 |
6307 | MSMO1 | P15T-E | Human | Esophagus | ESCC | 2.87e-22 | 7.55e-01 | 0.1149 |
6307 | MSMO1 | P16T-E | Human | Esophagus | ESCC | 1.33e-14 | 4.26e-01 | 0.1153 |
6307 | MSMO1 | P17T-E | Human | Esophagus | ESCC | 1.28e-02 | 1.32e-01 | 0.1278 |
6307 | MSMO1 | P19T-E | Human | Esophagus | ESCC | 2.17e-03 | 2.82e-01 | 0.1662 |
6307 | MSMO1 | P20T-E | Human | Esophagus | ESCC | 1.31e-06 | 1.61e-01 | 0.1124 |
6307 | MSMO1 | P21T-E | Human | Esophagus | ESCC | 1.49e-26 | 7.60e-01 | 0.1617 |
6307 | MSMO1 | P22T-E | Human | Esophagus | ESCC | 5.69e-56 | 1.29e+00 | 0.1236 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060668 | Esophagus | ESCC | alcohol metabolic process | 202/8552 | 353/18723 | 7.32e-06 | 7.26e-05 | 202 |
GO:00161263 | Esophagus | ESCC | sterol biosynthetic process | 46/8552 | 64/18723 | 1.91e-05 | 1.67e-04 | 46 |
GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
GO:00066953 | Esophagus | ESCC | cholesterol biosynthetic process | 41/8552 | 57/18723 | 5.25e-05 | 4.06e-04 | 41 |
GO:19026533 | Esophagus | ESCC | secondary alcohol biosynthetic process | 41/8552 | 57/18723 | 5.25e-05 | 4.06e-04 | 41 |
GO:19026524 | Esophagus | ESCC | secondary alcohol metabolic process | 87/8552 | 147/18723 | 6.58e-04 | 3.50e-03 | 87 |
GO:00461653 | Esophagus | ESCC | alcohol biosynthetic process | 83/8552 | 140/18723 | 8.04e-04 | 4.16e-03 | 83 |
GO:00066946 | Esophagus | ESCC | steroid biosynthetic process | 98/8552 | 173/18723 | 2.34e-03 | 1.03e-02 | 98 |
GO:00082034 | Esophagus | ESCC | cholesterol metabolic process | 79/8552 | 137/18723 | 3.11e-03 | 1.29e-02 | 79 |
GO:00161254 | Esophagus | ESCC | sterol metabolic process | 86/8552 | 152/18723 | 4.37e-03 | 1.73e-02 | 86 |
GO:19016174 | Esophagus | ESCC | organic hydroxy compound biosynthetic process | 128/8552 | 237/18723 | 5.86e-03 | 2.16e-02 | 128 |
GO:000820211 | Liver | Cirrhotic | steroid metabolic process | 143/4634 | 319/18723 | 2.79e-15 | 3.18e-13 | 143 |
GO:000663112 | Liver | Cirrhotic | fatty acid metabolic process | 165/4634 | 390/18723 | 1.29e-14 | 1.26e-12 | 165 |
GO:19026521 | Liver | Cirrhotic | secondary alcohol metabolic process | 75/4634 | 147/18723 | 5.62e-12 | 3.91e-10 | 75 |
GO:00082031 | Liver | Cirrhotic | cholesterol metabolic process | 70/4634 | 137/18723 | 2.59e-11 | 1.55e-09 | 70 |
GO:00161251 | Liver | Cirrhotic | sterol metabolic process | 75/4634 | 152/18723 | 4.54e-11 | 2.61e-09 | 75 |
GO:000606612 | Liver | Cirrhotic | alcohol metabolic process | 141/4634 | 353/18723 | 1.57e-10 | 8.03e-09 | 141 |
GO:00066941 | Liver | Cirrhotic | steroid biosynthetic process | 77/4634 | 173/18723 | 1.02e-08 | 3.91e-07 | 77 |
GO:0016126 | Liver | Cirrhotic | sterol biosynthetic process | 37/4634 | 64/18723 | 1.74e-08 | 6.32e-07 | 37 |
GO:0006695 | Liver | Cirrhotic | cholesterol biosynthetic process | 34/4634 | 57/18723 | 2.22e-08 | 7.77e-07 | 34 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa001005 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
hsa0010012 | Esophagus | ESCC | Steroid biosynthesis | 18/4205 | 20/8465 | 1.78e-04 | 6.79e-04 | 3.48e-04 | 18 |
hsa00100 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
hsa001001 | Liver | Cirrhotic | Steroid biosynthesis | 12/2530 | 20/8465 | 4.92e-03 | 1.76e-02 | 1.09e-02 | 12 |
hsa001002 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
hsa001003 | Liver | HCC | Steroid biosynthesis | 15/4020 | 20/8465 | 1.17e-02 | 2.97e-02 | 1.65e-02 | 15 |
hsa001004 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
hsa0010011 | Oral cavity | OSCC | Steroid biosynthesis | 15/3704 | 20/8465 | 4.62e-03 | 1.13e-02 | 5.75e-03 | 15 |
hsa0010021 | Oral cavity | LP | Steroid biosynthesis | 11/2418 | 20/8465 | 1.16e-02 | 3.91e-02 | 2.52e-02 | 11 |
hsa0010031 | Oral cavity | LP | Steroid biosynthesis | 11/2418 | 20/8465 | 1.16e-02 | 3.91e-02 | 2.52e-02 | 11 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MSMO1 | SNV | Missense_Mutation | c.8N>G | p.Thr3Arg | p.T3R | Q15800 | protein_coding | deleterious_low_confidence(0.02) | benign(0.043) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
MSMO1 | SNV | Missense_Mutation | c.141N>G | p.Phe47Leu | p.F47L | Q15800 | protein_coding | deleterious(0.03) | benign(0.02) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD | |
MSMO1 | SNV | Missense_Mutation | novel | c.583N>A | p.Leu195Ile | p.L195I | Q15800 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
MSMO1 | SNV | Missense_Mutation | novel | c.189N>A | p.Phe63Leu | p.F63L | Q15800 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MSMO1 | SNV | Missense_Mutation | novel | c.211T>G | p.Leu71Val | p.L71V | Q15800 | protein_coding | tolerated(0.15) | benign(0.007) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MSMO1 | SNV | Missense_Mutation | novel | c.659G>A | p.Arg220His | p.R220H | Q15800 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MSMO1 | SNV | Missense_Mutation | c.461A>G | p.Tyr154Cys | p.Y154C | Q15800 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MSMO1 | SNV | Missense_Mutation | c.809N>A | p.Arg270Gln | p.R270Q | Q15800 | protein_coding | tolerated(0.4) | benign(0.001) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
MSMO1 | SNV | Missense_Mutation | novel | c.785C>A | p.Ala262Asp | p.A262D | Q15800 | protein_coding | deleterious(0) | benign(0.36) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MSMO1 | SNV | Missense_Mutation | c.809N>A | p.Arg270Gln | p.R270Q | Q15800 | protein_coding | tolerated(0.4) | benign(0.001) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |